{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:35:48Z","timestamp":1792708548016,"version":"4.5.0"},"reference-count":44,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2006,10,3]],"date-time":"2006-10-03T00:00:00Z","timestamp":1159833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>An open\u2010label Phase II study of oxaliplatin was conducted to evaluate its safety and efficacy in children with recurrent or refractory medulloblastoma (MB), supratentorial primitive neuroectodermal tumors (SPNET), and atypical teratoid rhabdoid tumor (ATRT).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>Patients were stratified as follows: stratum IA, first recurrence MB with measurable disease; IB, recurrent MB with only cerebral spinal fluid (CSF) positivity or linear leptomeningeal disease (LLD); IC, MB \u2265second recurrence; stratum II, recurrent SPNET; stratum III, recurrent ATRT. Patients received oxaliplatin, 130 mg\/m<jats:sup>2<\/jats:sup> intravenously over 2 hours every 3 weeks. The primary objective was to estimate the sustained response rate in stratum 1A. Plasma ultrafiltrate platinum pharmacokinetics were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>A total of 43 patients with a median age of 8.5 years (range, 0.6\u201318.9 years) were enrolled. In stratum 1A, 2 of 15 had partial responses (PRs, 1 sustained PR). No responses were observed in other strata. The most frequent Grade 3 and 4 toxicities included thrombocytopenia (25.6%), neutropenia (16.3%), leukopenia (12%), increase in serum alanine transaminase (ALT) (7%), vomiting (4.7%), and sensory neuropathy (4.7%). No severe ototoxicity or nephrotoxicity was reported. Plasma ultrafiltrate platinum pharmacokinetic parameters were similar to adults, with a median clearance of 12.2 L\/hr (range, 4.4\u201330 L\/hr) and median area under the curve (AUC<jats:sub>0\u2010\u221e<\/jats:sub>) of 9.4 \u03bcg\/mL\/hr (range, 6.2\u201313.9 \u03bcg\/mL\/hr).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>Oxaliplatin was well tolerated in children but has limited activity in children with recurrent CNS embryonal tumors previously treated with platinum compounds. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.22241","type":"journal-article","created":{"date-parts":[[2006,10,3]],"date-time":"2006-10-03T20:28:03Z","timestamp":1159907283000},"page":"2291-2297","source":"Crossref","is-referenced-by-count":52,"title":["Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors"],"prefix":"10.1002","volume":"107","author":[{"given":"Maryam","family":"Fouladi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Blaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina Young","family":"Poussaint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Burgess B.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"McLendon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adekunle M.","family":"Adesina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K.","family":"Danks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Boyett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Gajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,10,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.220"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.6.1922"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1978.49.4.0589"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900201)65:3<412::AID-CNCR2820650306>3.0.CO;2-4"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(92)90940-J"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.222"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851001)56:7<1497::AID-CNCR2820560703>3.0.CO;2-7"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.1.62"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00149372"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.3.459"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19901215)66:12<2465::AID-CNCR2820661204>3.0.CO;2-N"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.2.249"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1994.81.5.0690"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2127"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.10.2696"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.5355"},{"key":"e_1_2_6_18_2","first-page":"9","article-title":"Accumulation of cis\u2010diamminedichloroplatinum(II) and platinum analogues by platinum\u2010resistant murine leukemia cells in vitro","volume":"48","author":"Kraker AJ","year":"1988","journal-title":"Cancer Res."},{"key":"e_1_2_6_19_2","first-page":"5970","article-title":"In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin","volume":"53","author":"Pendyala L","year":"1993","journal-title":"Cancer Res."},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(97)81490-6"},{"key":"e_1_2_6_21_2","first-page":"393","article-title":"Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non\u2010small cell lung cancer (NSCLC) sublines resistant to cisplatin","volume":"15","author":"Fukuda M","year":"1995","journal-title":"Anticancer Res."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005800520747"},{"key":"e_1_2_6_23_2","first-page":"3500","article-title":"Enhanced replicative bypass of platinum\u2010DNA adducts in cisplatin\u2010resistant human ovarian carcinoma cell lines","volume":"54","author":"Mamenta EL","year":"1994","journal-title":"Cancer Res."},{"key":"e_1_2_6_24_2","first-page":"799","article-title":"Role of carrier ligand in platinum resistance of human carcinoma cell lines","volume":"53","author":"Schmidt W","year":"1993","journal-title":"Cancer Res."},{"key":"e_1_2_6_25_2","first-page":"4881","article-title":"The role of DNA mismatch repair in platinum drug resistance","volume":"56","author":"Fink D","year":"1996","journal-title":"Cancer Res."},{"key":"e_1_2_6_26_2","first-page":"3087","article-title":"Loss of DNA mismatch repair in acquired resistance to cisplatin","volume":"56","author":"Aebi S","year":"1996","journal-title":"Cancer Res."},{"key":"e_1_2_6_27_2","first-page":"3579","article-title":"The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum\u2010DNA adducts","volume":"58","author":"Vaisman A","year":"1998","journal-title":"Cancer Res."},{"key":"e_1_2_6_28_2","first-page":"1841","article-title":"In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair","volume":"57","author":"Fink D","year":"1997","journal-title":"Cancer Res."},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-2797(82)90119-3"},{"key":"e_1_2_6_30_2","first-page":"96","article-title":"Oxaliplatin in colorectal cancer: an overview","volume":"27","author":"Armand JP","year":"2000","journal-title":"Semin Oncol."},{"key":"e_1_2_6_31_2","first-page":"23","article-title":"Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer","volume":"25","author":"Becouarn Y","year":"1998","journal-title":"Semin Oncol."},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.2938"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.8532"},{"key":"e_1_2_6_34_2","first-page":"1498","article-title":"Phase I study of oxaliplatin in pediatric patients with malignant solid tumors [Abstract]","author":"Pratt CB","year":"2001","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.2307\/3314658"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(00)00377-0"},{"key":"e_1_2_6_38_2","volume-title":"NONMEM Users' Guide.","author":"NONMEM Project Group","year":"1992"},{"key":"e_1_2_6_39_2","article-title":"Pharmacokinetics of oxaliplatin in children with solid tumors [Abstract]","volume":"21","author":"Iacono LC","year":"2002","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_40_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/08880010390203099","article-title":"Glomerular filtration rate in children with solid tumors: normative values and a new method for estimation","volume":"20","author":"Brandt JR","year":"2003","journal-title":"Pediatr Hematol Oncol."},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199403313301303"},{"key":"e_1_2_6_42_2","first-page":"1205","article-title":"Clinical pharmacokinetics of oxaliplatin: a critical review","volume":"6","author":"Graham MA","year":"2000","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_43_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00280-002-0550-3","article-title":"Population pharmacokinetics of oxaliplatin","volume":"51","author":"Delord JP","year":"2003","journal-title":"Cancer Chemother Pharmacol."},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200311000-00007"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050024"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.22241","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.22241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:10:09Z","timestamp":1760303409000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.22241"}},"subtitle":["A pediatric brain tumor consortium study"],"short-title":[],"issued":{"date-parts":[[2006,10,3]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["10.1002\/cncr.22241"],"URL":"https:\/\/doi.org\/10.1002\/cncr.22241","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,3]]}}}